Eiken Chemical Co., Ltd. · TSE:4549
Eiken Chemical — Q1 FY2025 Earnings Presentation
19 slides from Eiken Chemical's earnings presentation, Jul 31, 2024
Slide 1: Business Results for the First Three Months of fiscal year ending March 31, 2025
Business Results for the First Three Months of fiscal year ending March 31, 2025 EIKEN CHEMICAL CO., LTD. (Code: 4549) July 31, 2024
Slide 2: Earnings highlight for the first three months of the FY ending March 31, 2025
Earnings highlight for the first three months of the FY ending March 31, 2025 2
Slide 3: Executive summary for the first three months of the fiscal year ended March 31, 2025
Earnings highlight for the first three months of the fiscal year ended March 31, 2025 Executive summary for the first three months of the fiscal year ended March 31, 2025 • External environment ✓ Decrease of demand for COVID-19 detection kits ✓ Downside risks mainly caused by surging global resource
Slide 4: Consolidated financial highlights
Consolidated financial highlights Decrease in sales because domestic sales were steady, but overseas sales declined. Decrease in profit due to changes in sales mix because of decline in sales of high-profit products and patent fee income, and increased SG&A expenses (used as planned). FY ended Mar.
Slide 5: Earnings by segment—YoY change
Earnings by segment—YoY change The main product, fecal immunochemical tests (FIT) reagents, performed steady in Japan, but overseas sales decreased due to the timing of orders, etc. Molecular test sales decreased due to the decline in demand for COVID-19 tests and the expiration of patents. On the o
Slide 6: Earnings details by segment (1)
Earnings details by segment (1) Fecal immunochemical tests (FIT) reagents Immunological and serological reagents Sales in Japan remained steady, but sales decreased mainly Sales increased in due to increases in the number of facilities overseas due to the timing of orders. adopting the HbA1c test. N
Slide 7: Earnings details by segment (2)
Earnings details by segment (2) Urinalysis test strips Microbiological reagents Steady growth due to new adoption in Japan and increased Although sales of new rapid diagnostic kits increased, overall sales to overseas. sales remained at the same level as the same period last year due to the order ti
Slide 8: Earnings details by segment (3)
Earnings details by segment (3) Clinical chemistry test reagents Equipment/culture mediums related to food and environment Sales remained at the same level as the previous year despite Sales increased due to increased demand from increased the severe market environment. production in the food indust
Slide 9: Earnings details by segment (4)
Earnings details by segment (4) Molecular test (LAMP) Medical devices/Others Sales decreased due to the drop in demand for COVID-19 detection kits, and LAMP patent expiration. Sales remained at the same level as the same period last year. LAMP license incomes ： ¥1 million (¥108 million Same period p
Slide 10: Overseas results by region
Overseas results by region Europe: Sales of FIT decreased YoY due to inventory adjustments caused by waiting for next bidding, but this is expected to be temporary, and recovery is expected from the 2Q onward. North America: Sales of FIT decreased YoY due to the order timing, but there were no negat
Slide 11: Consolidated earnings forecast for the FY ending Mar.31 2025
Consolidated earnings forecast for the FY ending Mar.31 2025 11
Slide 12: Financial forecast for the fiscal year ending March 31, 2025
Financial forecast for the fiscal year ending March 31, 2025 Currently, no change to the full-year forecast for the fiscal year ending March 31, 2025. Expect to pick up from the 2Q onward due to factors such as recovery of FIT in overseas countries, increase in orders for TB-LAMP, and efficient use
Slide 13: Forecast by segment for the fiscal year ending March 31, 2025
Forecast by segment for the fiscal year ending March 31, 2025 In the FIT business, expected to pick up from the 2Q onward due to recovery from the restrained purchases due to the bidding period in major European countries, price increases taking advantage of the weak yen, expansion of the target age
Slide 14: Other topics
Other topics 1. Started construction of new manufacturing building at Nogi Division. 2. Decided to relocate head office. 3. Efforts to increase domestic screening participation rates. ~ Public health information website launched.~ 4. Continuously selected as a constituent of FTSE Blossom Japan Secto
Slide 15: Started construction of new manufacturing building at Nogi Division
Started construction of new manufacturing building at Nogi Division To accelerate the global development of FIT and secure production space for an anticipated corresponding large increase in production volume, it is started construction of new manufacturing building as a production base that consoli
Slide 16: Decided to relocate head office
Decided to relocate head office Relocate head office from the current Taito-ku location to Chiyoda-ku, Tokyo, in order to promote flexible work styles and improve management efficiency. ➢ New Address Ochanomizu Solacity 20F, 4-6 Kandasurugadai, Chiyoda-ku, Tokyo, Japan ➢ Opening Date Scheduled for S
Slide 17: Efforts to increase domestic screening participation rates
Efforts to increase domestic screening participation rates. ~Public health information website launched.~ Public health information website 「 」 launched. (Japanese Only) https://imakara.eiken.co.jp/ This website was launched to communicate to everyone what can do now to ensure a healthy future. As t
Slide 18: Continuously selected as a constituent of FTSE Blossom Japan Sector Relative Index
Continuously selected as a constituent of FTSE Blossom Japan Sector Relative Index Continuously included in the FTSE Blossom Japan Sector Relative Index in July 2024. The FTSE Blossom Japan Sector Relative Index is designed as a sector neutral benchmark that reflects the performance of companies dem
Slide 19: Saving Your Health
Saving Your Health Continuing to protect people's health as a global clinical diagnostics company Forward-Looking Statements • This material contains forward-looking statements about EIKEN CHEMICAL CO., LTD. (EIKEN). • These forward-looking statements are based on the current judgments and assumptio